X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Lead Product(s): VE202,Vancomycin Hydrochloride
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection (rCDI). It was granted orphan drug designation and fast track designation.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
The financing will be used to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AXA IM Alts
Deal Size: $106.5 million Upfront Cash: Undisclosed
Deal Type: Financing April 25, 2023
Details:
VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Vedanta reported positive topline results from Phase 2 CONSORTIUM trial, in which VE303 was associated with a 31.7% absolute risk reduction in rate of recurrence when compared with placebo, representing a greater than 80% reduction in odds of a CDI recurrence.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
Proceeds expected to be used primarily to support a Phase 3 trial of Vedanta’s lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD).
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: affiliates of Magnetar Capital
Deal Size: $68.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 21, 2021
Details:
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen. Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021.
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 12, 2021
Details:
The new UEG Week data presentation focuses on the kinetics and durability of colonisation from an 11-strain consortium of VE202 under various dosing and pre-treatment regimens.
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
